Advent International, a global private equity firm, Thursday announced the plan to merge two of its pharmaceutical portfolio companies, Cohance Lifesciences Ltd and Suven Pharmaceuticals ..
Suven Pharmaceuticals is a listed CDMO while Cohance Lifesciences is an unlisted company which was formed to create a new brand entity for three formerly Advent-acquired companies
Suven Pharmaceuticals is a listed CDMO and Cohance Lifesciences is an unlisted API and CDMO platform. Both are part of private equity firm Advent International s India portfolio.
ADIA and HarbourVest are in discussions to acquire a minority stake in Cohance Lifesciences, a pharmaceuticals platform owned by Advent International. The investors plan to invest $350-400 million, valuing Cohance Lifesciences at $1.5 billion. Advent International currently owns a 76% stake in Suven Pharmaceuticals, which was merged with Cohance Lifesciences.
PE firm Advent upbeat about Hyderabad's Life Sciences sector, plans to invest more thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.